Pound Loss — JournalArta
Eli Lilly said its experimental EloraTZP (tirzepatide plus eloralintide) cut weight by up to 54.1 lb at 48 weeks in a Phase 2 trial in people with obesity and Type 2 diabetes. The FDA issued a new GLP-1 eye warning; Lilly reported Q3 2026 revenue of $24.4B, up 39%.
How this was made

The 30-second read
Why it matters
For traders, the main decision is whether to price in continued obesity-pipeline upside while adjusting for incremental regulatory/safety risk across the GLP-1 class.
Market read
New obesity trial efficacy datapoints can support momentum in LLY, but the FDA’s GLP-1 warning adds a persistent risk premium.
What to watch
Phase 2 EloraTZP is early-stage and unapproved; the key near-term driver is whether later-stage trials confirm efficacy and safety, especially given the new eye-condition warning.
Background
The article frames Lilly’s obesity pipeline progress (EloraTZP Phase 2, retatrutide Phase 3) alongside a recent FDA-required GLP-1 warning for a rare eye condition.
Ticker impact
Eli Lilly reported Phase 2 EloraTZP weight-loss data and Phase 3 retatrutide results at ObesityWeek, plus a new FDA GLP-1 eye-warning.
Likely choppy trading, with upside bias from new obesity pipeline efficacy data offset by caution from the FDA’s GLP-1 eye-condition warning.
The article cites specific trial efficacy endpoints for EloraTZP and retatrutide, while also noting the FDA required a new warning for the GLP-1 class including Lilly’s Mounjaro and Zepbound.
Market effects
Reinforces competitive intensity in obesity GLP-1 and next-gen incretin pipelines, while highlighting ongoing class-wide safety monitoring.
US-focused read-through for healthcare/biopharma risk appetite tied to obesity drug sentiment.
ObesityWeek data and FDA safety messaging can influence global GLP-1/obesity peers’ risk premiums and trial expectations.
Counterpoint
The FDA warning is class-wide and not proven causal, so the market may over-discount it relative to the magnitude of new efficacy data.
Key entities
- companyEli Lilly
Reported early and late-stage obesity drug trial data (EloraTZP, retatrutide) and is directly referenced in the FDA GLP-1 warning.
- regulatorFDA
Required a new warning for GLP-1 drugs regarding a rare eye condition with sudden vision loss.
- conferenceObesityWeek
Venue where Lilly presented the trial results cited in the article.




